A prospective study of novel disease activity indices for ankylosing spondylitis
Authors (first, second and last of 4)
Rheumatology International is an independent journal reflecting world-wide progress in the research, diagnosis and treatment of the various rheumatic diseases.
It serves an international, interdisciplinary group of workers involved in problems of rheumatic diseases. Coverage includes the management of rheumatic diseases, and extends to all modern trends in clinical research. Contributions include original publications, short communications, editorials, letters to the editors and reviews. No case reports will be accepted.
- An independent journal reporting on worldwide research, diagnosis and management of rheumatic diseases
- Covers disease management as well as trends in clinical research
- Presents original research, editorials, letters and reviews
- Average time from submission to 1st decision: 21 days
- 97% of authors who answered a survey reported that they would definitely publish or probably publish in the journal again
Journal information
- Editor-in-Chief
-
- Armen Yuri Gasparyan
- Publishing model
- Hybrid. Open Access options available
Journal metrics
- 1.984 (2019)
- Impact factor
- 2.056 (2019)
- Five year impact factor
- 23 days
- Submission to first decision
- 67 days
- Submission to acceptance
- 365,888 (2019)
- Downloads
Latest issue
Latest articles
-
-
Immune checkpoint inhibitor-induced musculoskeletal manifestations
Authors (first, second and last of 5)
-
Does immunosuppressive treatment entail an additional risk for children with rheumatic diseases? A survey-based study in the era of COVID-19
Authors (first, second and last of 9)
-
Comparison of the efficacy and safety of biologic agents between elderly-onset and young-onset RA patients: the ANSWER cohort study
Authors (first, second and last of 17)
-
The influence of perioperative interventions targeting psychological distress on clinical outcome after total knee arthroplasty
Authors (first, second and last of 6)
Journal updates
-
COVID-19 and impact on peer review
As a result of the significant disruption that is being caused by the COVID-19 pandemic we are very aware that many researchers will have difficulty in meeting the timelines associated with our peer review process during normal times. Please do let us know if you need additional time. Our systems will continue to remind you of the original timelines but we intend to be highly flexible at this time.
-
Call for COVID-19 cases
The COVID-19 Global Rheumatology Alliance has launched an international registry for clinicians to enter data about their rheumatology patients with COVID-19. Add your case here: https://rheum-covid.org.
About this journal
- Electronic ISSN
- 1437-160X
- Abstracted and indexed in
-
- BIOSIS
- Biological Abstracts
- CAB Abstracts
- CNKI
- Chemical Abstracts Service (CAS)
- Current Contents/ Life Sciences
- Current Contents/Clinical Medicine
- Dimensions
- EBSCO Academic Search
- EBSCO Biomedical Reference Collection
- EBSCO Discovery Service
- EBSCO STM Source
- EMBASE
- Google Scholar
- Institute of Scientific and Technical Information of China
- Japanese Science and Technology Agency (JST)
- Journal Citation Reports/Science Edition
- Medline
- Naver
- OCLC WorldCat Discovery Service
- Pathway Studio
- ProQuest Central
- ProQuest Health & Medical Collection
- ProQuest Health Research Premium Collection
- ProQuest Medical Database
- ProQuest Pharma Collection
- ProQuest-ExLibris Primo
- ProQuest-ExLibris Summon
- Psyndex
- Reaxys
- SCImago
- SCOPUS
- Science Citation Index
- Science Citation Index Expanded (SciSearch)
- Semantic Scholar
- UGC-CARE List (India)
- Copyright information
